Reduction of Plasma Levels of Soluble Tumor Necrosis Factor and Interleukin‐2 Receptors by Means of a Novel Immunoadsorption Column

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Therapeutic apheresis and dialysis

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1744-9987.2008.00640.xPMID 19140848
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Soluble tumor necrosis factor receptor type I enhances tumor development and persistence in vivo.

  2000cited by this paper
• The role of therapeutic apheresis in the treatment of cancer: a review.

  1999cited by this paper
• LOW MOLECULAR WEIGHT PROTEIN APHERESIS AND REGRESSION OF BREAST CANCER

  1996cited by this paper
• Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients.

  1994cited by this paper
• Soluble tumour necrosis factor receptors as prognostic factors in cancer patients.

  1994cited by this paper
• The phylogeny of oncology.

  1990cited by this paper
• The phylogeny of oncology.

  1990cited by this paper
• Type I interferons (alpha and beta) in HIV disease

  1990cited by this paper
• Apheresis of low molecular weight protein fraction and the onset of labor.

  1990cited by this paper
• Apheresis of low molecular weight protein fraction and the onset of labor.

  1990cited by this paper
• Continuous whole blood UltraPheresis procedure in patients with metastatic cancer.

  1989cited by this paper
• Continuous whole blood UltraPheresis procedure in patients with metastatic cancer.

  1989cited by this paper
• In vivo and in vitro studies on nonspecific blocking factors of host origin in cancer patients. Role of plasma exchange as an immunotherapeutic modality.

  1978cited by this paper

• Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy

  2021cites this paper
• SERUM LEVELS OF TUMOR NECROSIS FACTOR (TNF-A) AND ITS SOLUBLE RECEPTORS STNF-R1 AND STNF-R2 IN CANCER PATIENTS

  2012cites this paper
• The Italian registry of therapeutic apheresis: Granulocyte–monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study

  2011cites this paper
• The paper published by Drs Lentz and Kumar in the December 2008 issue.

  2009cites this paper
• The tumour necrosis factor as a mediator of vessel inflammation: importance of exposed receptor residues for its neutralization

  2009cites this paper
• Letter to the Editor

  2009cites this paper